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Background: The financial burden of medical expenses has been increasing for cancer patients. We investigated
the relationship between household income and financial burden among patients with chronic myelogenous
leukaemia (CML) who have been treated with imatinib.
Methods: A questionnaire was distributed to 1200 patients between May and August 2009. We retrospectively
surveyed their household incomes, out-of-pocket medical expenses, final co-payments after refunds, and the
perceived financial burden of their medical expenses in 2000, 2005 and 2008.
Results: A total of 577 patients completed the questionnaire. Their median age was 61 years (range, 15–94). A
financial burden was felt by 41.2 % (28 of 68) of the patients treated with imatinib in 2000, 70.8 % (201 of 284) in
2005, and 75.8 % (400 of 528) in 2008. Overall, 182 patients (31.7 %) considered its discontinuation because of the
financial burden and 15 (2.6 %) temporarily stopped their imatinib prescription. In 2000, 2005 and 2008, the patients’
median annual household incomes were 49,615 US Dollars (USD), 38,510 USD and 36,731 USD, respectively, with an
average currency exchange rate of 104 Yen/USD in 2008. Their median annual out-of-pocket expenses were 11,548,
12,067 and 11,538 USD and their median final annual co-payments were 4,375, 4,327 and 3,558 USD, respectively.
Older patients (OR = 0.96, 95 % CI: 0.95–0.98, p< 0.0001 for 1-year increments), and patients with higher household
incomes (OR = 0.92, 95 % CI: 0.85–0.99, p= 0.03 for 10,000 USD-increments) were less likely to have considered
discontinuing their imatinib treatment. Conversely, patients with higher annual final co-payments (OR = 2.21, 95 %
CI: 1.28–4.28, p= 0.004 for 10,000 USD-increments) were more likely to have considered discontinuing their imatinib
treatment.
Conclusions: The proportion of CML patients who sensed a financial burden increased between 2000 and 2008.
During this period, their annual incomes fell by 13,000 USD, although their medical expenses did not change.
Financial support for patients being treated with expensive drugs remains a major problem in Japan.
Keywords: Economic recession, Hematology, Anticancer drug, Health insuranceBackground
Following the global financial crisis triggered by the col-
lapse of Lehman Brothers in 2008, many developed coun-
tries have faced a severe economic recession. The Japanese
economy has consequently shown signs of further stagna-
tion. Along with a nationwide recession, household income* Correspondence: alice-smn@umin.net
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reproduction in any medium, provided the orin Japan has declined since 2000. Japan’s financial problems
have in fact been worsened by the recent earthquake, tsu-
nami, and Fukushima nuclear crisis of March 2011. Mean-
while, because of population-aging, social welfare costs
have accounted for higher proportions of government
spending in developed countries than ever before. To
maintain the financial balance of their insurance systems,
governmental agencies in many nations carefully review all
applications for approval of expensive medications, such as
anticancer drugs [1-3].l Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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system in 1961. By law, all Japanese citizens must join pub-
lic health insurance programs and can access all hospitals,
regardless of income or insurance policy [4]. This system
has been frequently revised to adapt to social changes [4].
At present, all patients have to pay a part of their medical
costs; these payments vary according to patient age, and
range from 10 % to 30 % of the costs: 20 % for those under
6 years old, 30 % for 6 to 69 year olds, 20 % for 70 to
74 year olds, and 10 % for those over 75 years old.
Patient household income and age regulate the self-
payment upper limit, which varies from 77 US dollars
(USD) to 1,442 USD per month at the timing of writing,
based on the average exchange rate in 2008: 1 USD= 104
Yen (Table 1) [5]. If patients exceed this limit, any over-
payments are later reimbursed [5]. The final co-payment
is calculated as the total payment minus the amount of
the refund. If the patient receives welfare because of hav-
ing a low income or as a survivor of the atomic bomb-
ings of Hiroshima and Nagasaki, his or her medical
expenses are fully covered by the government and no
out-of-pocket charges are required.
Cancer treatment has changed with the development
of molecular targeting agents. Specifically, imatinib has
dramatically altered the treatment of chronic myelogen-
ous leukaemia (CML) [6,7]. Long-term use of imatinib
enables CML patients to live longer in remission [8].
Compared with conventional treatment with interferon-
α, imatinib has resulted in fewer side effects and a
higher quality of life for CML patients [9,10]. In recent
years, it has been become the standard drug treatment
for CML, although its cost remains a major problem;
400 mg of imatinib, the standard daily dose, costs 146.1
USD [11].
The costs of cancer treatment have been determined in
many studies [12]. However, information on the relationshipTable 1 Reimbursement system for medical expenditures
Age Income
Under 70 years old High (monthly income over 530,000 Yen; 5,09
Middle
Low (people who are excluded from inhabita
Over 70 years old High (monthly income over 280,000 Yen; 2,69
Middle
Lower (people who are excluded from inhab
Low (no gross income)
The currency was calculated based on the average exchange rate in 2008: 1 USD= 1between patient incomes and the financial burdens of and
reactions to expensive therapies is limited. We hypothesised
that patients’ income and the financial burden of their treat-
ment could influence their willingness to undergo such
medical interventions. In this study, we focused on CML
patients who have been prescribed imatinib.Methods
Patients and ethics
This study was approved by the ethical review board of
the Institute of Medical Science of The University of
Tokyo (Approval number: 20-70-210417). The survey
was conducted during May to August 2009 and included
any patients with CML who were prescribed imatinib. In
Japan, imatinib mesylate (GlivecW) was approved for
coverage by public medical insurance and registered in
the National Health Insurance Reimbursement List for
the treatment of CML in December 2001.
We asked 345 hospitals across Japan with haematology
departments to participate in our survey. Of them, 144
(41.7 %) agreed to participate, and questionnaires were dis-
tributed to 1200 CML patients. The patients completed
the survey during their regular clinic visits. Nine associa-
tions for patients with blood diseases were also asked to
take part in our survey. One major CML patient associ-
ation participated in our survey, while the other eight asso-
ciations did not. The questionnaires were posted to the
patients who belonged to this association and agreed to
participate. The questionnaires were completely anonym-
ous and returned by mail. They were sent out on May 1,
2009, and the deadline for response was August 10, 2009.
A total of 577 CML patients completed the questionnaire
(response rate: 48.1 %). Two patients were excluded from
the study because they had never been prescribed imatinib.
In total, 575 responses were analysed.Self-payment upper limit per month
6 USD) 150,000 Yen (1,442 USD) + [medical expenses –
500,000 Yen (4,808 USD)] × 1 %
80,100 Yen (770 USD) + [medical expenses –
267,000 Yen (2,567 USD)] × 1 %
nt tax) 35,400 Yen (340 USD)
2 USD) 80,100 Yen (770 USD) + [medical expenses – 267,000
Yen (2,567 USD)] × 1 %, if the patient is hospitalized
44,400 Yen (427 USD) for outpatient clinic only
44,400 Yen (427 USD) , if the patient is hospitalized
12,000 Yen (115 USD) for outpatient clinic only
itant tax) 24,600 Yen (237 USD) , if the patient is hospitalized
8,000 Yen (77 USD) for outpatient clinic only
15,000 Yen (144 USD) , if the patient is hospitalized
8,000 Yen (77 USD) for outpatient clinic only
04 Yen.
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We prepared a questionnaire with 18 items assessing
income, medical costs, and financial burden after a
series of discussions among medical staff and econo-
mists (Additional file 1: Tables S1 and TableS2). As
mentioned above, the questionnaires were distributed
to CML patients through their doctors or a patient as-
sociation. We asked the patients to refer to their previ-
ous tax returns when they responded to the questions
on income or medical expenses to obtain accurate
data.
To assess the financial burden of imatinib prescrip-
tion, we surveyed the patients’ annual pre-tax household
incomes from all sources in 2000, 2005, and 2008, as
well as their out-of-pocket medical costs and final co-
payments. Household incomes and medical expenses
were expressed in Japanese Yen in the questionnaire,
while they are in USD in this article. We converted the
incomes using the average currency exchange rate of
2008, which was 104 Japanese Yen per USD. Financial
burden was based on the subjective views of the
patients. The impact of CML and imatinib side effects
on patient occupations was also studied. Side effects
were based on patient reports.
The patients who were treated with imatinib in 2000
either received the medicine from a clinical trial or
they imported it under their physician’s advice. The
patients in the clinical trial did not need to pay for the
imatinib, but they did pay for other medical costs and
received reimbursements for these if they exceeded the
ceiling of medical expenditure. The patients who
imported imatinib paid for the drug as well for the
transaction, and they could not apply to the reim-
bursement program.Table 2 Demographic and socioeconomic characteristics of th
Variables
Age Median (range)
Gender: Men, Women n (%)
Socioeconomic Status
Household Income (2008) (USD) Median (range)
Occupation
Working full-time n (%)
Working part-time n (%)
Homemaker n (%)
Other n (%)
Retired or currently not working n (%)
Education
University graduate or higher n (%)
Other n (%)
Living with family: Yes, No n (%)
The currency was calculated based on the average exchange rate in 2008: 1 USD= 1Statistical analysis
Data were analysed using JMP ver. 8.0 (SAS Institute,
Inc., Cary, NC) and PASW Statistics 18 (SPSS, Inc.,
Chicago, IL). All incomes and costs are expressed as an-
nual amounts, which are summarised for each year
(2000, 2005 and 2008). To compare the ratio of annual
out-of-pocket expenses to household income for these
three years, we performed repeated analyses of variance
(ANOVA).
A multiple logistic regression analysis was used to de-
termine the variables that independently affected patient
consideration to discontinue imatinib treatment, cor-
recting for interactions between the variables. Before
the multivariate analysis, univariate analyses were per-
formed with the following variables: age, sex, imatinib
dose, the presence of side effects, academic background,
occupation, residence of patients with families, annual
household income in 2008, out-of-pocket costs, final co-
payment, and patient knowledge of medical subsidy
programs. The multiple logistic regression analysis was
performed after the determination of collinearity be-
tween variables that were p< 0.25 in the univariate ana-
lyses, using the Pearson's correlation coefficient and a
generalized linear model. The variables were evaluated
with conditional odds ratios (OR) and 95 % confidence
intervals (CI). Confidence intervals above 1.0 suggested
that the variable was associated with an increased likeli-
hood of considering the discontinuation of imatinib
treatment, while those below 1.0 suggested that the vari-
able was associated with a decreased likelihood of con-
sidering the discontinuation of imatinib treatment.
Confidence intervals that included an OR of 1.0 were
not considered statistically significant. Statistical signifi-
cance was set at p< 0.05 for all statistics.e patients
No. of valid responses (n)
61 (15–94) 573











439 (80.3), 108 (19.7) 547
04 Yen.




<400 mg/day 215 (37.4)
400 mg/day 335 (58.3)
>500 mg/day 22 (3.8)
No response 3 (0.5)
Year of CML diagnosis
Before 1990 4 (0.7)
1991 to 1995 15 (2.6)
1996 to 2000 68 (11.8)
2001 to 2005 242 (42.1)
After 2006 236 (41.0)
No response 10 (1.7)




Frequency of Visits as an Out-patient
<1 month 65 (11.3)
More than 1 month, but less than 2 months 320 (55.7)
More than 2 month, but less than 3 months 132 (23.0)
More than 3 month, but less than 4 months 52 (9.0)
No response 6 (1.0)
Side effects*
Facial oedema 370 (64.3)





Muscular pain 141 (24.5)
Generalised oedema 136 (23.7)
Joint pain 80 (13.9)
Taste disorder 67 (11.7)
Stomach pain 49 (8.5)
Other 137 (23.8)
* The question on side effects allowed multiple answers.
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Patient backgrounds
The demographic details of the CML patients are shown in
Table 2. The median age was 61 years (range, 15–94), and
428 patients (74.4 %) were≤ 70 years old. Five patients had
no household income and did not receive pensions or other
social support; they spent their savings on daily living
expenses. A total of 112 CML patients (19.5 %) answered
that they have stopped working or been unemployed be-
cause of the onset of CML and 34 (5.9 %) have stopped
working or been unemployed because of imatinib side
effects.
A summary of the patients’ CML treatment and side
effects is shown in Table 3. A total of 452 patients (78.6 %)
were diagnosed with CML after imatinib sales started in
Japan on December 7, 2001. The median period of imati-
nib administration was 46.5 months (range, 1–115). A
total of 525 patients (91.3 %) experienced side effects.
Patient perspectives on the financial burden of imatinib
treatment and discontinuation of the prescription
In 2000, 28 patients out of the 68 who were given an
imatinib prescription (41.2 %) felt that their medical
expenses constituted a heavy financial burden, although
not all medical expenses reflected the cost of imatinib
because imatinib was not approved in Japan in 2000.
This number and ratio have increased more recently,
rising to 201 out of 284 (70.8 %) in 2005, and 400 out of
528 (75.8 %) in 2008.
A total of 261 patients (45.4 %) had considered discon-
tinuing their imatinib prescription; 127 (22.1 %) because
of its side effects and 204 (35.5 %) because of other rea-
son(s) (Figure 1). A total of 182 patients (31.7 %) consid-
ered its discontinuation because of the financial burden
that its use created. Seventy-six patients (13.2 %) actu-
ally stopped their imatinib prescription. Of them, 40
(7.0 %) stopped based on their physicians’ advice be-
cause of the side effects, 18 (3.1 %) stopped of their own
accord because of the side effects, and 18 (3.1 %)
stopped for other reasons, e.g., to prepare for surgery, or
because there was no treatment response. Imatinib
treatment was temporarily suspended by 15 (2.6 %)
patients because of financial reasons.Financial situation and medical expenses in 2000, 2005
and 2008
Patients’ annual household incomes have dropped since
2000; however, their out-of-pocket expenses and final co-
payments have remained unchanged (Figure 2). The
changes in median household income, out-of-pocket
expenses and final co-payments between 2000 and 2008
were −21,058, +2,212 and −337 USD, respectively. Five
patients who had no household income spent their savings
on medical expenses.The relationships between 2008 household incomes and
out-of-pocket expenses and final co-payments are shown
in Figure 3. There was no clear correlation between final
co-payments and income (p=0.40). Higher ratios of out-
of-pocket expenses and final co-payments were observed
in patients with lower household incomes.
Financial situations of patients who were treated with
imatinib throughout 2000 to 2008
In all, 33 patients answered that they were treated with
imatinib throughout the study period; that is, from 2000
Figure 1 Patient perspectives on the discontinuation of imatinib treatment. A bar chart of patient perspectives on the discontinuation of
imatinib treatment is shown. The proportion of patients indicating each reason is shown on the X axis.
Kodama et al. BMC Cancer 2012, 12:152 Page 5 of 10
http://www.biomedcentral.com/1471-2407/12/152to 2008. Among them, 22 were analysed after excluding
11 patients whose medical insurance had changed during
the study period. The ratios of annual out-of-pocket
expenses for medical costs to annual household income
[median, (range)] were 16.8 % (range, 0.0–85.9), 18.4 %
(range, 0.0–72.0), and 22.0 % (range, 0.0–120.0) in 2000,
2005 and 2008, respectively. No significant differences
were found between the three years in a repeated
ANOVA (p= 0.23). The ratio of out-of-pocket expenses
to household income in 2005 increased for 11 patients
and decreased for another 11 compared with the ratio in
2000. When comparing the same ratio for 2005 and
2008, an increase for 13 patients and a decrease for
seven patients occurred. The ratio of out-of-pocket
expenses did not change for two patients.
Factors considered in the discontinuation of imatinib
The results of the univariate analyses performed to identify
the factors associated with patients’ having considered dis-
continuing their imatinib prescription are shown in
Additional file 1: Table S3. Variables with a p value< 0.25
in the univariate models were selected as candidates for the
multivariate regression analyses. Final co-payments for
medical expenses in 2008 and out-of-pocket medical
expenses in 2008 were significantly correlated (Pearson’s
r=0.810 and p< 0.001). Therefore, to avoid collinearity,
only final co-payment was selected for further analysis. Both
education and occupation showed significant impacts on
household income in 2008 (both p values< 0.001 in a gen-
eralized linear model), and household income was selected
for the multivariate model even though its univariate
p value was> 0.25. Consequently, five factors were consid-
ered in the multivariate regression model. Among them, the
following three factors were statistically significant predic-
tors of having considered discontinuing imatinib treatment(Table 4): age (OR=0.96, 95 % CI: 0.95–0.98, p< 0.0001),
household income (per 10,000 USD) (OR=0.92, 95 % CI:
0.85–0.99, p=0.03), and final co-payments for medical
expenses (per 10,000 USD) (OR=2.21, 95 % CI: 1.28–4.28,
p=0.004). The 95 % CIs for these three variables do not
include an OR of 1, thus we conclude that the likelihood
of having considered discontinuing imatinib treatment
decreased with increasing patient age and income, and
increased with final co-payments for medical expenses.
Discussion
This is the first study to demonstrate that the use of ima-
tinib places a large financial burden on Japanese CML
patients, who live in a nation with universal health insur-
ance coverage. In countries where patients must pay a
part of their medical expenses, such as Japan, those who
require expensive medications incur an enormous finan-
cial burden. For example, out-of-pocket expenses and
final co-payments among patients receiving imatinib in
2008 were approximately 12,000 and 3,600 USD, respect-
ively. Their annual out-of-pocket expenses were about
10 times those of an average healthy Japanese person
[13]. These medical expenses continue for as long as the
patients are prescribed imatinib, creating an economic
problem that is also observed in many other developed
countries [14].
Of the 204 patients who had considered discontinuing
their imatinib treatment for reasons other than side effects,
182 (90 %) had considered it for financial reasons. The
proportion of patients who felt that the financial burden
was getting higher every year was approximately 40 % in
2000 and 76 % in 2008. The proportion of patients who ac-
tually stopped their imatinib prescription for financial rea-
sons was 2.6 %. In a US study, 31 % of CML patients
stopped their imatinib treatment [15]. It should be noted
Figure 2 Annual incomes and medical costs of CML patients.
Box plots of medical expenses and incomes by study year are
shown. The number of valid responses for each year is indicated on
the upper row of each box. The box plots represent the median,
25th and 75th percentiles (the box) as well as the range without
outliers (the whiskers). The outliers were defined as 1st or 3 rd
quartile ± 1.5 × interquartile range. The currency was calculated based
on the average exchange rate in 2008:1 USD= 104 Yen.
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guarantees all Japanese citizens access to any hospital and
standard therapies that are regulated by the national gov-
ernment, regardless of their income or type of private
medical insurance. These findings suggest that having a
sense of financial burden might affect patients’ compliance
with continuing to take the high-cost medication, even
though they can change their hospitals easily to keep up
the medication in cases of conflict between patients andhospital staff. Therefore, the provision of medical insur-
ance programs specifically for patients with severe eco-
nomic hardship who require costly medications should be
considered.
This study showed that many CML patients had insuf-
ficient financial resources to pay for their imatinib treat-
ments. The average annual household income in Japan
in 2008 was 55,000 USD [13], which vastly exceeds that
of this study’s CML patients (37,500 USD) (Figure 2). In
all, 13 % of patients were in the low-income group with
a household income of 22,000 USD or less [16]. Further-
more, patients’ financial situations are worsening; house-
hold income in Japan dropped by an average of 6,673
USD between 2000 and 2008 [17] while the median in-
come of the CML patients fell by approximately 13,000
USD in the same period (Figure 2). It will become in-
creasingly difficult for the patients to continue paying for
their medical expenses. Because imatinib was not
approved for sale in Japan until 2001, the data on med-
ical expenditures in 2000 should be interpreted with cau-
tion. Unknown bias may be present because of to the
small population of patients who were treated with ima-
tinib in 2000, as well as the unequal co-payment/reim-
bursement conditions in 2000 versus 2005 and 2008.
The data on medical costs in 2000 may be affected by
these differences in co-payment/reimbursement
conditions.
There are several possible reasons why the financial
situations of the CML patients have deteriorated. One
explanation may be that their household income has
decreased because of the onset of unemployment after
their diagnosis of CML. In our study, 112 CML patients,
who accounted for 20 % of the total valid responses, had
quit their jobs because of the onset of CML, although
the unemployment rate in this study is lower than that
reported among patients with other malignant diseases
[18]. Even if they could obtain new jobs to adjust their
working conditions to their treatment, some of them
may be re-employed at a lower wage. Another reason
may be that the on-going recession in Japan caused the
elevated unemployment rate, because the poor economy
makes it difficult for cancer patients to find new jobs or
to return to their former ones. One must also mention
the side effects of imatinib as a third factor. Most physi-
cians believe that imatinib has minimal side effects and
that the patients can live normal lives during treatment
[7]. The symptomatic side effects reported in this study
are similar to those indicated in the national registry of
the Pharmaceutical Medical Devices Agency of Japan, al-
though we could not collect confirmatory laboratory data
[19]. However, the actual lifestyles of the patients were
quite different from physicians’ expectations; no fewer
than 6.0 % of the patients had to quit their jobs because
of imatinib side effects, with the majority of them unable
Figure 3 Medical expenses in 2008 by quintile groups of annual income.The classification of annual income on the X axis is based on the
2008 annual report of family income and expenditure in Japan. The currency was calculated based on the average exchange rate in 2008:1
USD= 104 Yen. The box plots represent the median, 25th and 75th percentiles (the box) as well as the range without outliers (the whiskers). The
number of valid answers for each income group was 93, 96, 79, 41 and 59 across smaller to larger X axis categories.
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Table 4 Factors associated with patient consideration to
discontinue imatinib treatment for a reason other than
side effects
Variables Tested value Odds ratio
(95 % CI)
p value
Age One year of
increased age
0.96 (0.95–0.98) <0.0001
Daily imatinib dose 100 mg of
increased dose
0.97 (0.73–1.29) 0.83











Variables that were included in the multiple regression model identifying
factors associated with patient consideration to discontinue imatinib for a
reason other than side effects are shown.
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have a greater impact on patients’ careers than is evident
in the medical literature. Another possible reason is re-
tirement during the study period, because patients aged
between 56 and 73 years old in 2009 may have retired
during the period of interest.
The multivariate analysis showed that household in-
come, total medical expenses, and age affected the con-
sideration to discontinue imatinib treatment. Younger
patients and patients with lower incomes were more
likely to have considered discontinuing their imatinib
treatment, whereas patients with higher incomes were
less likely to have considered discontinuing their treat-
ment (Table 4). In addition, 25.3 % of our cohort had
incomes of 25,000 USD or less in 2008, and the median
ratio of their out-of-pocket expenses to their incomes
was approximately 50 % (Figure 3). Thus, low-income
patients face great difficulty in pursuing normal lives in
the long-term.
Supplemental support for low-income patients who are
not covered by social security and are being treated with
expensive drugs for a long term should be considered, be-
cause the current refund system was designed for high
medical expenses with short-term duration, such as surgi-
cal operations, not for new high-cost drugs for the treat-
ment of cancer or rheumatoid arthritis. Although the
development of a new support system for low-income
patients would bring about additional cost to the govern-
ment, we believe the system is still feasible, because it was
reported that non-adherent CML patients prescribed ima-
tinib might be more costly to the health care system than
adherent patients [15].
The CML patient association has proposed a method
to reduce medical expenses among its members. Since
the summer of 2007, the association has informed mem-
bers of the benefits of a three-month imatinib prescrip-
tion. The three-month prescription is beneficial becauserefunds are calculated on a monthly basis and the max-
imum limit of the refunds is not affected by medical
costs, meaning that prescribing imatinib in a particular
month as much as possible can bring higher patient
refunds. The refund system can be applied when patients
pay medical expenses over the maximum limit four times
or more per year; thus, a three-month prescription is the
most reasonable way to reduce annual final co-payments.
This information was shared with CML patients and
might be related to the reduction of final co-payments in
2008 by 800 USD compared with 2005 (Figure 2). Pro-
posing imatinib subscriptions every three months
increases the payment of each clinic visit by about 1,923
USD; however, the annual final co-payment is reduced
by approximately 3,846 USD because the patients can
obtain larger annual refunds compared with those fol-
lowing monthly prescriptions. A similar movement by
patient associations to decrease the financial burden of
imatinib exists in Korea [20]. Unfortunately, not all
patients have been able to reduce their annual final co-
payment using three-month imatinib prescriptions. In
fact, 49.6 % of patients continue to visit hospitals every
month, even though their CML symptoms show no signs
of worsening. It is possible that these patients regularly
visit hospitals to reduce their medical expenses for each
visit, even though a three-month interval between visits
is sufficient from a medical standpoint [21].
From the perspective of patient accessibility, the Japanese
universal health insurance system is beneficial because it
guarantees that patients can access any hospital/clinic.
However, financial difficulties among low-income patients
who are treated with expensive medicines might affect the
accessibility of long-term advanced medication, suggesting
a limitation of the current universal insurance system in
Japan. Health care reform to support low-income patients
is required.
Dasatinib and nilotinib, which are newly developed
tyrosine kinase inhibitors for CML, were approved for
use in Japan in March 2009 and March 2011, respect-
ively [22,23]. The prices of these medicines regulated by
the national institute for approved dosage per day are as
follows: dasatinib (100 mg) 18,448 Yen and nilotinib
(800 mg) 18,428 Yen [24]. For reference, that of imatinib
(400 mg) is 10,996 Yen. The patients treated with dasati-
nib or nilotinib can also receive reimbursement if their
medical expenses exceed the upper limit of co-payment.
There are several limitations to this study. To begin
with, it is a small-cohort, retrospective survey that relies
on a questionnaire. Income and medical expenses were
simply based on patient responses, although we did ask
the patients to refer to their previous tax-return docu-
ments to obtain accurate data. The other limitation is
that this study included only Japanese patients, and the
social system, culture, and patient backgrounds of Japan
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37.4 % of the patients in our survey were prescribed an
imatinib dose of 300 mg/day or less. This dose level, as
well as the age and gender composition of our partici-
pants, is similar to previous reports from Japan [9,25],
but the dose is less than that reported in similar studies
in the United States and Europe [8]. Importantly, the
health insurance system in Japan is different from other
countries, meaning that the flow of medical expenditures
and refunds in the household budget is different. Thus,
careful consideration is needed when comparing the fi-
nancial burdens of imatinib internationally.
Conclusions
In this report, we showed that the proportion of CML
patients who sensed a financial burden increased be-
tween 2000 and 2008, meanwhile their annual incomes
fell by 13,000 USD even their medical expenses did not
change. The findings presented here suggests that finan-
cial support for those patients being treated with expen-
sive drugs still remains a major problem in Japan. This
study is a small-cohort, retrospective survey, however,
issues such as aging populations, excessive budget defi-
cits, the high prices of newly developed medications, and
elevated out-of-pocket expenses are common problems
in developed countries. These issues must be overcome;
otherwise, newly developed, revolutionary drugs will not
be able to bring benefits to large numbers of patients.
Detailed discussions of public financial support are
needed to reduce the financial burden on patients.
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